846
Views
9
CrossRef citations to date
0
Altmetric
Drug Evaluation

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

, , , , &
Pages 1291-1301 | Received 11 Apr 2016, Accepted 04 Aug 2016, Published online: 17 Aug 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Huihan Wang, Hua Shi, Xiaowei He & Aijun Liao. (2021) Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide. OncoTargets and Therapy 14, pages 2789-2795.
Read now

Articles from other publishers (8)

Siying Zhu, Yu Chen, Juanfeng Lao, Chenglin Wu, Xiaoxia Zhan, Yongjian Wu, Yuqi Shang, Zhengyu Zou, Jinyu Zhou, Xiang Ji, Xi Huang, Xiaomin Shi & Minhao Wu. (2021) Signaling Lymphocytic Activation Molecule Family-7 Alleviates Corneal Inflammation by Promoting M2 Polarization. The Journal of Infectious Diseases 223:5, pages 854-865.
Crossref
Lekha Mikkilineni & James N. Kochenderfer. (2020) CAR T cell therapies for patients with multiple myeloma. Nature Reviews Clinical Oncology 18:2, pages 71-84.
Crossref
Lijie Xing, Liang Lin, Tengteng Yu, Yuyin Li, Shih-Feng Cho, Jiye Liu, Kenneth Wen, Phillip A. Hsieh, Krista Kinneer, Nikhil Munshi, Kenneth C. Anderson & Yu-Tzu Tai. (2020) A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia 34:8, pages 2150-2162.
Crossref
Janna L. Huskey, Raymond L. Heilman, Hasan Khamash & Rafael Fonseca. (2018) Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma. Transplantation 102:12, pages 1994-2001.
Crossref
David Ritchie & Marco Colonna. (2018) Mechanisms of Action and Clinical Development of Elotuzumab. Clinical and Translational Science 11:3, pages 261-266.
Crossref
Svetomir N. Markovic & Anagha Bangalore Kumar. 2018. The Basics of Cancer Immunotherapy. The Basics of Cancer Immunotherapy 21 37 .
Thomas MartinRachid BazDon M. BensonNikoletta LendvaiJeffrey WolfPamela MunsterAlexander M. LesokhinClaudine WackEric Charpentier, Frank Campana & Ravi Vij. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:25, pages 3294-3303.
Crossref
Stewart Sell. (2017) Cancer immunotherapy: Breakthrough or “deja vu, all over again”?. Tumor Biology 39:6, pages 101042831770776.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.